Written by:
Dr. Sophie Reynolds

Dr. Sophie Reynolds is a board-certified medical doctor specializing in internal medicine. With over a decade of experience in patient care and medical writing

Combinib 250 mg Tablet

Brand Name:   Combinib
Molecule:   Lapatinib
Strength:   250 mg
Quantity:   30 Tablets
Form:   Tablet
Packaging Type:   Bottle
Manufacturer/Marketed By:   Cipla
Country of Origin:   India

Description

Combinib 250 mg Tablet contains Lapatinib, a targeted anticancer agent used in the treatment of HER2-positive breast cancer. It is a tyrosine kinase inhibitor (TKI) that blocks specific proteins responsible for cancer cell growth and spread. Combinib is typically used in combination with other anticancer drugs in patients who have advanced or metastatic breast cancer.

Benefits

  • Specifically targets HER2-positive cancer cells

  • Delays progression of metastatic breast cancer

  • Oral administration allows at-home treatment

  • Often used when resistance to trastuzumab or chemotherapy occurs

  • Can be combined with hormone therapy or chemotherapy

Indications and Usage

Combinib (Lapatinib) is indicated for the treatment of:

  • Advanced or metastatic HER2-positive breast cancer

    • In combination with capecitabine in patients previously treated with anthracyclines, taxanes, and trastuzumab

    • In combination with letrozole for postmenopausal women with hormone receptor–positive, HER2-positive metastatic breast cancer

It must be prescribed and monitored by a qualified oncologist.

How it Works

Lapatinib blocks the HER2/neu and EGFR (ErbB1) tyrosine kinases — proteins that promote growth and survival of cancer cells. By inhibiting these signaling pathways, Combinib slows or stops tumor cell growth, especially in HER2-positive breast cancer.

Dosage & Administration

  • Dosage is determined by your oncologist based on your condition and combination therapy

  • Typically taken once daily on an empty stomach (1 hour before or 1 hour after meals)

  • Must be swallowed whole with water — do not crush or chew

  • Do not skip or stop treatment unless advised by your doctor

  • Regular monitoring of liver function and cardiac status may be required

Side Effects

Common side effects:

  • Diarrhea

  • Nausea or vomiting

  • Rash or skin irritation

  • Loss of appetite

  • Fatigue

  • Mouth sores

Serious side effects (seek medical attention):

  • Liver enzyme elevation or liver toxicity

  • Dehydration due to severe diarrhea

  • Heart rhythm changes (rare)

  • Interstitial lung disease (rare)

Warning and Precaution

  • Not recommended in pregnancy or breastfeeding

  • May cause liver damage — monitor liver enzymes

  • Use with caution in patients with heart disease or lung problems

  • May cause severe diarrhea — hydration and antidiarrheal medications may be needed

  • Inform your doctor about all medications and supplements

  • Avoid grapefruit juice as it may affect drug levels

Related Products

Related Posts:

Ruxolitinib Tablets Receive FDA Approval for Hematologic Malignancies

The U.S. Food and Drug Administration (FDA) has approved Ruxolitinib tablets for the treatment of certain hematologic malignancies, marking another

READ MORE »
Tovorafenib Approved in Europe for Children with BRAF-Altered Low-Grade Glioma

n Medical Review: This article was reviewed by Dr. Sophie Reynolds on May 14, 2026.n n This marks an important

READ MORE »
FDA Approves Vepdegestrant for ER+/HER2–, ESR1-Mutated Breast Cancer: A New Targeted Option

Medical Review: This article was reviewed by Dr. Sophie Reynolds on May 6, 2026. Breast cancer treatment continues to evolve

READ MORE »
0 reviews
0
0
0
0
0

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.